Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets

In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help debt leverage ratios but also free up capacity to do other strategic deals.

By Jacob Bell • April 1, 2026

Ambrosia adds a megaround for obesity drugs

The $100 million Series B round will be used to bring the biotech’s oral GLP-1 into early human testing.

By Gwendolyn Wu • Updated 7 hours ago

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma

A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications for public health. 

By Delilah Alvarado , Shaun Lucas • April 1, 2026

FDA, after turbulent year, leaves drugmakers guessing on its direction

Constant leadership changes and erratic decision-making have left the biopharmaceutical industry feeling its chief regulator is as unpredictable as it’s ever been.

By Jonathan Gardner , Shaun Lucas • April 1, 2026

Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout

The deal secures two sleep disorder drugs that would fill a hole in the company’s portfolio and intensify a competition with Takeda and Eisai.

By Jonathan Gardner • March 31, 2026

Viridian tumbles on positive data for key eye drug prospect

The data did not meet investor expectations, and could bring “fierce investor debate on commercial feasibility,” according to an analyst.

By Delilah Alvarado • March 31, 2026

Biogen, with $5.6B Apellis buy, builds out immunology offerings

Chief Financial Officer Robin Kramer explained how the deal not only provides two marketed products, but a team with nephrology expertise that will be valuable as Biogen prepares to launch felzartamab.

By Jacob Bell • March 31, 2026

Merck strikes deal with antibody discovery startup

In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed antibodies for multiple targets.

By Gwendolyn Wu • March 31, 2026

mRNA is poised to rise beyond infectious diseases, if it’s not derailed by R&D cuts

Research into areas like cancer could become collateral damage of a broader anti-mRNA push, according to a new study.

By Alexandra Pecci • March 31, 2026

Biotech IPOs stayed at slow pace, but grew larger in the first quarter of 2026

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing what’s been observed over a similar timeframe in prior years, according to BioPharma Dive data.

By Gwendolyn Wu • March 31, 2026

Blackstone closes $6.3B fund for life sciences investing

It's the biggest life sciences private fund ever raised, coming in nearly 40% larger than its Blackstone predecessor vehicle.

By Jacob Bell • March 30, 2026

United rises on IPF results; Biogen scores positive lupus data and an approval

Tyvaso, a marketed PAH therapy from United Therapeutics, continued to show potential in another lung condition. Elsewhere, Aurinia inked an acquisition and Lilly built its case for Ebglyss.

By Jacob Bell • March 30, 2026

Lilly’s AI commitment expands through deal with Insilico

A collaboration “across multiple therapeutic areas” could net the Hong Kong-based biotech more than $2 billion as Lilly seeks to sustain its industry lead.

By Jonathan Gardner • March 30, 2026

Obesity drugmaker Kailera plans an IPO

The company, led by Ron Renaud, raised $1 billion in venture funding to develop a competitor to Wegovy and Zepbound that’s now in late-stage testing.

By Gwendolyn Wu • March 30, 2026

Novartis targets Xolair successor in buyout of startup Excellergy

Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche’s popular medicine. 

By Gwendolyn Wu • March 27, 2026

Merck’s deal for Terns sparks debate over a possible biotech bidding war

Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are convinced a better proposal is coming. 

By Jonathan Gardner • March 26, 2026

FDA clears Denali drug in ‘clear step’ for rare disease biotechs

The approval of Denali’s Hunter syndrome treatment, Avlayah, comes after a series of drug rejections and delays that had led to criticism of the FDA’s stance on rare disease therapies.

By Kristin Jensen • March 26, 2026

Wave crashes on obesity drug update; Kodiak’s reboot pays dividends

Wave’s drug, which is meant to improve body composition, disappointed investors but was defended by analysts. Elsewhere, Kodiak’s revived vision loss treatment succeeded in a second Phase 3 trial.

By BioPharma Dive staff • March 26, 2026

Maze tumbles despite positive data for kidney disease drug

Investors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease.

By Delilah Alvarado • March 25, 2026

Beam posts positive data on base editing treatment for AATD

Updated data showed the biotech's approach to the rare lung and liver condition helped restore functional protective proteins in a small study.

By Gwendolyn Wu • March 25, 2026

Sarepta sees early success with RNAi drugs from Arrowhead

Long-awaited results from Phase 1/2 studies lifted Sarepta’s stock and, according to the company, suggest potential for two medicines to treat muscle-weakening conditions.

By Kristin Jensen • March 25, 2026

RA Capital targets China with latest SPAC deal

The prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a securities filing.

By Gwendolyn Wu • March 24, 2026

Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases

Acquiring Ouro Medicines, which launched last year, hands Gilead an antibody designed to bind to BCMA and CD3, a pair of immune cell proteins that are popular targets for drugmakers.

By Gwendolyn Wu • March 24, 2026

Immutrin raises $87M to advance drug for progressive heart disease

The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, “ATTR-CM,” that has become a battleground for companies like Pfizer, Alnylam and BridgeBio.

By Delilah Alvarado • March 24, 2026

Karyopharm myeloma drug yields mixed data in myelofibrosis trial

Xpovio combined with Incyte’s Jakafi helped on one key measure but missed on other goal in a disorder that, by one analyst’s estimates, could triple the company’s revenue.

By Jonathan Gardner • March 24, 2026